Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy:

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00356018
Recruitment Status : Completed
First Posted : July 25, 2006
Last Update Posted : March 4, 2020
Sponsor:
Collaborator:
Abbott
Information provided by:
Orlando Health, Inc.

Brief Summary:
To determine, in a randomized, parallel open-label fashion, compliance rates between once-daily extended-release divalproex sodium tablets (Depakote-ER®, Abbott Labs) versus multiple-daily dose valproic acid capsules (Depakene®, Abbott Labs) in an epilepsy population.

Condition or disease Intervention/treatment
Epilepsy Behavioral: Compliance

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 5 participants
Observational Model: Other
Time Perspective: Prospective
Official Title: Compliance With Once-Daily Divalproex Extended-Release Tablets (Depakote-ER) Versus Multiple-Daily Dose Valproic Acid Capsules (Depakene) in Epilepsy: A Randomized, Parallel, Prospectively-Controlled Outpatient Comparison
Study Start Date : July 2006
Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Epilepsy





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 99 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
The population includes both patients whose seizures are relatively well controlled on their present conventional, enteric-coated twice-daily or three-times daily Divalproex sodium regimen.
Criteria

Inclusion Criteria:1) Patients, age 16 and above, currently taking Divalproex-DR for any seizure disorder; 2) Other AEDs are permitted concurrently, although compliance with these will not be recorded. Other medications for co-morbid disease are permitted, provided no plans for changes in medications used for the treatment of the concomitant disorder are expected.

3) Patients must demonstrate a 75% or greater compliance rate with DR via calendar during the week of familiarity with the MEMs unit. The threshold value of 75% has been chosen since research shows that people take approximately 75% of their AED(s) as prescribed (13,14), and the same numerical value is frequently used in determining whether or not to retain a patient in clinical Phase 2a-3b industry-sponsored study.

-

Exclusion Criteria:1) patients with a recent history of status epilepticus; 2) patients who have refractory or unstable epilepsy; 3) patients with acute illnesses requiring changes in concurrent drugs; 4) patients unwilling to change from their present DR regimen to divalproex-ER or IR-VPA.

5) Patients unwilling or unable to utilize the MEMs monitoring unit; 6) Pregnant or lactating women.

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00356018


Locations
Layout table for location information
United States, Florida
Orlando Regional Lucerne Hospital
Orlando, Florida, United States, 32801
Sponsors and Collaborators
Orlando Health, Inc.
Abbott
Investigators
Layout table for investigator information
Principal Investigator: Jane Boggs, MD Physician
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00356018    
Other Study ID Numbers: 3D20-2006
First Posted: July 25, 2006    Key Record Dates
Last Update Posted: March 4, 2020
Last Verified: March 2020
Keywords provided by Orlando Health, Inc.:
Epilepsy
Compliance
Additional relevant MeSH terms:
Layout table for MeSH terms
Epilepsy
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases